Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

Record summary

This open-label clinical study administered psilocybin to people with treatment-resistant depression and measured symptoms alongside brain imaging. It is relevant to consciousness research because participants’ altered states were embedded in a therapeutic context, allowing comparison between acute subjective effects, subsequent mood change and neural measures. The study was not a blinded efficacy trial and cannot establish that psychedelic experience alone caused improvement. Verify recruitment criteria, therapist support, timing of scans, outcome measures and the authors’ causal limitations.